Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Kavanagh

Showing results (141-150 of 193) with videos related to

Pageof 20
Sort By:
The Journal of Clinical Investigation|February 5, 2019
Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in miceKate Smith-Jackson, Yi Yang, Harriet Denton, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 22, 2025
Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUSGiovany Orozco-Leal, Luke Vale, Yemi Oluboyede, et al.
BMJ Open|September 19, 2022
Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm studySarah Dunn, Victoria Brocklebank, Andrew Bryant, et al.
American Journal of Physiology. Renal Physiology|April 29, 2016
Wnt6 regulates epithelial cell differentiation and is dysregulated in renal fibrosisHayley Beaton, Darrell Andrews, Martin Parsons, et al.
Human Molecular Genetics|November 25, 2024
The role of complement factor I rare genetic variants in age related macular degeneration in FinlandAnneliza Andreadi, Thomas M Hallam, Vicky Brocklebank, et al.
Blood|October 29, 2009
Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndromeIain Moore, Lisa Strain, Isabel Pappworth, et al.
Brain : a Journal of Neurology|June 6, 2025
Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel diseaseSarah McGlasson, Katy Reid, Anna Klingseisen, et al.
Journal of Nephrology|September 24, 2002
The influence of pre-operative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival following renal transplantationY Mun Woo, Douglas McLean, David Kavanagh, et al.
Journal of the American Society of Nephrology : JASN|June 10, 2006
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndromeVéronique Fremeaux-Bacchi, Elizabeth A Moulton, David Kavanagh, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 7, 2012
Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?David Kavanagh, Isabel Y Pappworth, Holly Anderson, et al.
Pageof 20

Showing results (141-150 of 193) with videos related to

Sort By:
Pageof 20
The Journal of Clinical Investigation|February 5, 2019
Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in miceKate Smith-Jackson, Yi Yang, Harriet Denton, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 22, 2025
Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUSGiovany Orozco-Leal, Luke Vale, Yemi Oluboyede, et al.
BMJ Open|September 19, 2022
Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm studySarah Dunn, Victoria Brocklebank, Andrew Bryant, et al.
American Journal of Physiology. Renal Physiology|April 29, 2016
Wnt6 regulates epithelial cell differentiation and is dysregulated in renal fibrosisHayley Beaton, Darrell Andrews, Martin Parsons, et al.
Human Molecular Genetics|November 25, 2024
The role of complement factor I rare genetic variants in age related macular degeneration in FinlandAnneliza Andreadi, Thomas M Hallam, Vicky Brocklebank, et al.
Blood|October 29, 2009
Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndromeIain Moore, Lisa Strain, Isabel Pappworth, et al.
Brain : a Journal of Neurology|June 6, 2025
Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel diseaseSarah McGlasson, Katy Reid, Anna Klingseisen, et al.
Journal of Nephrology|September 24, 2002
The influence of pre-operative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival following renal transplantationY Mun Woo, Douglas McLean, David Kavanagh, et al.
Journal of the American Society of Nephrology : JASN|June 10, 2006
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndromeVéronique Fremeaux-Bacchi, Elizabeth A Moulton, David Kavanagh, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 7, 2012
Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?David Kavanagh, Isabel Y Pappworth, Holly Anderson, et al.
Pageof 20